Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenues        
Total revenues $ 25,438 $ 2,527 $ 55,728 $ 8,101
Cost of sales        
Total cost of sales 21,483 4,828 49,988 21,510
Gross profit/(loss) 3,955 (2,301) 5,740 (13,409)
Operating expenses        
Research and development 19,311 9,195 45,820 31,362
Sales and marketing 13,224 2,542 29,567 9,994
General and administrative 19,833 5,415 46,821 11,004
In-process research and development assets acquired 15,181   25,581  
Total operating expenses 67,549 17,152 147,789 52,360
Loss from operations (63,594) (19,453) (142,049) (65,769)
Change in fair value of warrant liability     (56,576)  
Interest expense (12) (98) (137) (253)
Interest and other (expense) income, net (3,796) 94 (3,166) 995
Loss before income taxes (67,402) (19,457) (201,928) (65,027)
Income tax benefit 523 0 32,761 0
Net loss $ (66,879) $ (19,457) $ (169,167) $ (65,027)
Net loss per share-Basic $ (0.26) $ (0.12) $ (0.67) $ (0.41)
Net loss per share-Diluted $ (0.26) $ (0.12) $ (0.67) $ (0.41)
Weighted average shares outstanding basic 260,555,655 159,968,300 251,467,644 158,120,826
Weighted average shares outstanding diluted 260,555,655 159,968,300 251,467,644 158,120,826
Products        
Revenues        
Total revenues $ 23,949 $ 1,888 $ 51,820 $ 6,113
Cost of sales        
Total cost of sales 20,450 3,732 46,427 18,145
Services        
Revenues        
Total revenues 1,489 639 3,908 1,988
Cost of sales        
Total cost of sales $ 1,033 $ 1,096 $ 3,561 $ 3,365